Back to Search Start Over

CD3/CD19 bispecific BiTE (R) Antibody Blinatumomab Treatment of Non-Hodgkin Lymphoma (NHL) Patients : 60 mu g/m(2)and day by Continuous Infusion is Tolerable and Results in Durable Responses

Authors :
Knop, S.
Goebeler, M.
Viardot, A.
Noppeney, Richard
Topp, M. S.
Nagorsen, D.
Scheele, J. S.
Libicher, M.
Zugmaier, G.
Klinger, M.
Schmidt, M.
Klappers, P.
Kufer, P.
Einsele, H.
Bargou, R. C.
Publication Year :
2010

Subjects

Subjects :
Medizin

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.unidue...bib..22910060369e8b397249866e019cc824

Tools

Authors Abstract Subjects Details